MERS-CoV (NCoV / Novel coronavirus) Spike Antibody, Rabbit MAb

RRID Number: AB_2860455
EliteRmab®, manufactured by recombinant technology

MERS-CoV (NCoV / Novel coronavirus) Spike Antibody, Rabbit MAb 产品信息

MERS-CoV (NCoV / Novel coronavirus) Spike Antibody, Rabbit MAb
(Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.)
MERS-CoV Coronavirus spike
Has cross-reactivity in ELISA with
MERS-CoV Spike Protein (aa 1-1297, 40069-V08B)
MERS-CoV Spike Protein S1 (aa 1-725, 40069-V08B1)
MERS-CoV Spike Protein RBD (aa 367-606, 40071-V31B1)
No cross-reactivity in ELISA with
MERS-CoV Spike Protein S2 (aa 726-1296, 40070-V08B)
Recombinant MERS-CoV (NCoV / Novel coronavirus) Spike Protein (ECD, aa 1-1297) (Catalog#40069-V08B)
This antibody was obtained from a rabbit immunized with purified, recombinant recombinant MERS-CoV (NCoV / Novel coronavirus) Spike Protein (Catalog#40069-V08B; AFS88936.1; Met1-Trp1297).
Monoclonal Rabbit IgG Clone #723
Protein A
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

MERS-CoV (NCoV / Novel coronavirus) Spike Antibody, Rabbit MAb 经验证的应用

Microneutralizaiton (MN): Neutralization of MERS-CoV pseudovirus by R723. Positive Control:293T/DPP4 cells were infected with MERS-CoV pseudovirus; Negative Control:293T/DPP4 cells without MERS-CoV pseudovirus; R723: MERS-CoV pseudovirus infection in 293T/DPP4 cells was inhibited by R723.
Please Note: Optimal concentrations/dilutions should be determined by the end user.

MERS-CoV (NCoV / Novel coronavirus) Spike Antibody, Rabbit MAb 图片

Measured by its ability to inhibit infection of Caco-2 cells induced by MERS-CoV pseudovirus. The ED50 for this effect is 2.5-11 ng/mL.

MERS-CoV (NCoV / Novel coronavirus) Spike Antibody, Rabbit MAb: 别称

Anti-coronavirus s1 Antibody; Anti-coronavirus s2 Antibody; Anti-coronavirus spike Antibody; Anti-cov spike Antibody; Anti-ncov RBD Antibody; Anti-ncov s1 Antibody; Anti-ncov s2 Antibody; Anti-ncov spike Antibody; Anti-RBD Antibody; Anti-S Antibody; Anti-s1 Antibody; Anti-Spike RBD Antibody

Coronavirus spike 背景信息

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.
  • Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
    Folegatti, PM;Bittaye, M;Flaxman, A;Lopez, FR;Bellamy, D;Kupke, A;Mair, C;Makinson, R;Sheridan, J;Rohde, C;Halwe, S;Jeong, Y;Park, YS;Kim, JO;Song, M;Boyd, A;Tran, N;Silman, D;Poulton, I;Datoo, M;Marshal, J;Themistocleous, Y;Lawrie, A;Roberts, R;Berrie, E;Becker, S;Lambe, T;Hill, A;Ewer, K;Gilbert, S;
    The Lancet Infectious Diseases
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.